Biotech

More news about this topic

Biopharma

Obesity investing’s way forward, mapped

August 19, 2026

GLP-1 approaches have hit a traffic jam.

Article

Learn more »
Biotech

European biotech chases record VC funding

July 14, 2026

Investment in the region’s biotech startups is on course to hit new highs, but it still lags US deal activity by a wide margin.

Article

Learn more »
Commentary

Parabilis now the largest VC-backed biotech IPO

June 10, 2026

The stock jumped 58% in its first day of trading on the Nasdaq Global Select Market on Wednesday.

Article

Learn more »
Venture Capital

Some investors are turning to biotech as a hedge against potential AI bubbles

May 29, 2026

They’re betting that with the continuous need for health care, the sector is more immune.

Article

Learn more »
VC Exits

Biotech IPOs poised for a comeback—but only for some

April 15, 2026

A GLP-1 maker and a protein biomarker detection company are the latest to head for biotech IPOs. M&A activity is helping bolster that.

Article

Learn more »
Weekend Analysis

Why AI drug discovery isn’t the layup that VCs expected

January 9, 2026

Biotech investors have poured lots of cash into AI drug discovery bets. Will it pay off?

Article

Learn more »
VC Fundraising

Backing a crew of high-profile IPO hopefuls, Lux is poised for banner year

January 7, 2026

Lux closed on $1.5B for Fund IX, the deep-tech firm announced Wednesday

Article

Learn more »
Biotech

European VC biotech dealmaking rebounds to record highs

October 31, 2025

AI adoption, exit momentum and regulatory support have improved investor appetite.

Article

Learn more »
Weekend Analysis

As big pharma’s next patent cliff looms, biotech investors see dollar signs

September 12, 2025

Some $180 billion in pharma revenue is going off patent in 2027 and 2028.

Article

Learn more »
Biotech

The US posted zero biopharma IPOs in Q2. That hasn’t happened since 2016

August 15, 2025

Poor stock performance and elevated interest rates are keeping investors at bay.

Article

Learn more »
Biotech

With lenders galore, life science companies find debt cheaper

July 2, 2025

Lenders cut spreads and eased covenants for borrowers amid increased competition from other debt providers and pressure to deploy capital.

Article

Learn more »
Biotech

VCs have almost completely abandoned biotech investing

June 4, 2025

VC fundraising by firms with biotech strategies hasn’t been this slow since 2013

Article

Learn more »
Analyst Note

PitchBook Analyst Note: The Evolution of Biotech VC Funds

May 28, 2025

This analysis provides investors and fund managers with a data-driven view of biotech VC performance and structural trends.

Research

Learn more »
Biotech

Federal funding cuts could destroy the lab-grown unicorn

April 2, 2025

In 2023, federal sources accounted for more than half of the total $108 billion that U.S. academic institutions spent on R&D. Much of that spending is at risk.

Article

Learn more »
Biotech

Verdiva Bio joins weight loss race with $411M Series A

January 9, 2025

The London-based company’s launch coincides with a sharp increase of VC funding for weight loss companies.

Article

Learn more »
Private Equity

RFK Jr. nomination dents PE confidence in CRO market

December 12, 2024

Vaccine scrutiny could raise clinical trial standards, which poses a risk to fund managers with significant investments in CROs.

Article

Learn more »
Healthcare

Pharma services dealmaking nears quarterly record

November 18, 2024

PE deal activity in the sector is riding tailwinds from M&A-friendly interest rate policies and GPs’ growing appetite for life sciences investments.

Article

Learn more »
Biotech

Has PE fallen out of love with Europe’s biotech industry?

September 26, 2024

Data from the last five years shows that investment in biotech is dropping sharply with no signs of recovery.

Article

Learn more »